-
Mashup Score: 2Dermatology Times, March 2023 (Vol. 44. No. 03) - 1 year(s) ago
AcneAnti-AgingAtopic Dermatitis BPDCNHair & ScalpNP and PAPsoriasis Rare DiseaseRosaceaSkin Cancer (Melanoma)Skin Cancer (Non-Melanoma)VitiligoWound CareDevice TechnologyDrug WatchLegalLifestyleNP and PAPractice Management 2 Minute DrillAround the PracticeBetween The LinesCase Based Peer PerspectiveDermviewDermview: VitiligoEditorial Board NewsExpert InterviewsFrontline ForumInside the…
Source: Dermatology TimesCategories: Dermatology, Latest HeadlinesTweet
-
Mashup Score: 0AAOS Login - 1 year(s) ago
LoginUsername Forgot my Username Password Forgot my Password Remember Me Remember Me
Source: login.auth.aaos.orgCategories: Latest Headlines, OrthopedicsTweet-
The AAOS Biologics Dashboard is a member-exclusive benefit that enables orthopaedic surgeons to determine the approval status of biologic products. Stephen Weber, MD, FAAOS, explains why it's important that surgeons utilize this resource. https://t.co/ky39uMyCo7 #AAOS #Biologics https://t.co/FaMNVfjeFA
-
-
Mashup Score: 0A case series of dual biologics therapy for severe asthma - 1 year(s) ago
Treatment with monoclonal antibodies (mAb) targeting IgE, IL-5, and IL-4/IL-13 pathways has become the standard strategy to manage severe asthmatics refractory to conventional therapies. Biologics are effective in improving symptom control, exacerbation rates, and oral corticosteroid (OCS) dependence.1 However, a subset of patients show suboptimal response, manifesting as persistent OCS use and…
Categories: Allergy-Immunology, Latest HeadlinesTweet
-
Mashup Score: 0Home - JDDonline - Journal of Drugs in Dermatology - 1 year(s) ago
The Journal of Drugs in Dermatology (JDD) is a monthly, peer-reviewed, indexed dermatology journal and online resource.
Categories: Dermatology, Latest HeadlinesTweet
-
Mashup Score: 0‘Why not combine them?’: Early dual biologic therapy may overcome limits in severe IBD - 1 year(s) ago
DENVER — Early data suggest combination therapy with biologics or advanced small-molecules may be safe and effective in patients with inflammatory bowel disease, according to a presenter at the Crohn’s and Colitis Congress.“We have all these different mechanisms of action right now — in newer development are some of the oral and p-19 [inhibitors],” Edward V. Loftus
Source: www.healio.comCategories: Gastroenterology, Latest HeadlinesTweet
-
Mashup Score: 0Home - JDDonline - Journal of Drugs in Dermatology - 1 year(s) ago
The Journal of Drugs in Dermatology (JDD) is a monthly, peer-reviewed, indexed dermatology journal and online resource.
Categories: Dermatology, Latest HeadlinesTweet
-
Mashup Score: 0Chronic Rhinosinusitis With Nasal Polyps - ACAAI Public Website - 1 year(s) ago
An estimated 50 percent of patients with eosinophilic esophagitis also have seasonal allergies or asthma.
Source: ACAAI Public WebsiteCategories: Allergy-Immunology, Latest HeadlinesTweet
-
Mashup Score: 0Patients with Rheumatic, Gastroenterological Conditions Less Familiar with Biosimilars Compared with Biologics - 1 year(s) ago
Although patients with inflammatory conditions reported positive attitudes towards biologic treatment, they were far less familiar with biosimilars, indicating the need for clinicians to provide patient education more effectively.
Source: HCP LiveCategories: Latest Headlines, RheumatologyTweet
-
Mashup Score: 0
Allergic fungal rhinosinusitis (AFRS) is a noninvasive subtype of chronic rhinosinusitis with nasal polyps (CRSwNP) that usually develops in immunocompetent atopic individuals and is more common in geographic regions characterized by warm temperatures and high humidity, conducive to higher environmental fungal presence. Allergic fungal rhinosinusitis usually presents with unique computed…
Categories: Allergy-Immunology, Latest HeadlinesTweet
-
Mashup Score: 1Safety of Biologics for Atopic Diseases During Pregnancy - 1 year(s) ago
The high prevalence of atopic diseases in women of childbearing age reveals the need to determine the safety of biologics during pregnancy. This review summarizes the effects of 7 Food and Drug Administration–approved biologics (omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab, tezepelumab, and tralokinumab) on maternal and fetal outcomes. For this purpose, we reviewed…
Categories: Allergy-Immunology, Latest HeadlinesTweet
The March issue of Dermatology Times is live! Discover more about #nutrition and #AtopicDermatitis, scoring #alopecia, and #biologics. Download now or follow along as more content is posted throughout the month. https://t.co/Woda6SgK1D https://t.co/2XqQ4F6M6c